HPV legislation in Oregon

From SourceWatch
Jump to: navigation, search

Women in Government Ratings

Women in Government, a non-profit network of state level women legislators, receives significant funding from the pharmaceutical industry, including Merck, GlaxoSmithKline, and Digene Corporation -- all with products related to HPV vaccination and testing. According to their report, "The 'State' of Cervical Cancer Prevention in America - 2008" [1]:


POPULATION: 3,700,758


Incidence & Mortality (2008 Score / 2007 Score)

  • Cervical Cancer Incidence Rate: 6.3/100,000 (2 / 2)
  • Cervical Cancer Incidence Rate/Race: White: 6.2, Black: 13.3, Hispanic: 10.4
  • Cervical Cancer Mortality Rate: 1.5/100,000 (2 / 1)
  • Cervical Cancer Mortality Rate/Race: White: 1.4


Screening (2008 Score / 2007 Score)

  • Cervical Cancer Screening Rate: 83.4% (1 / 1)
  • Cervical Cancer Screening Rate/Race: White: 83.4%, Hispanic: 85.4%
  • % Uninsured/Unscreened: 32.9% (0 / 0)
  • Medicaid Coverage HPV Testing: Unrestricted (2 / 2)


Healthcare Access (2008 Score / 2007 Score)

  • Rate Uninsured Women: 21% (0 / 1)
  • % Low Income/Uninsured Women: 42%


Policy Initiatives and Infrastructure (2008 Score / Cumulative Score (2005–2008)

Screening Requirements (0 / 1)

  • There are no new screening requirements.

Task Forces (0 / 1)

  • There is no new cervical cancer prevention task force legislation.

Access to HPV Vaccines (1 / 1)

  • HB 3253 would require health benefit plans to provide coverage of the HPV vaccine for female beneficiaries 11 years old and older; referred to House Committee on Human Services and Women’s Wellness.

HPV Vaccine Information Programs (0 / 0)

  • There is no HPV vaccine information activity.

Miscellaneous (0 / 0)

  • There is no new miscellaneous cervical cancer prevention activity.


Annual Ratings

  • 2008: Fair (10 out of 22 points)
  • 2007: Good (9 out of 18 points)


Articles and resources

SourceWatch Resources

External links

References